Rapid infusion of rituximab over 60 min
Author:
Publisher
Wiley
Subject
Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2009.01215.x/fullpdf
Reference12 articles.
1. Brief communication: rituximab in HIV-associated multicentric Castleman disease;Bower;Ann Intern Med,2007
2. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis;Edwards;N Engl J Med,2004
3. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Hiddemann;Blood,2005
4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006
5. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rapid rituximab administration: Safety of 60-minute infusions in malignant and benign haematological disease;Journal of Oncology Pharmacy Practice;2024-06-07
2. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial;Journal of Neurology;2024-04-22
3. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review;Future Oncology;2022-08
4. The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe;Hematological Oncology;2022-03-17
5. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton’s tyrosine kinase inhibitor, in pemphigus;Journal of Dermatological Science;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3